ANCA-ASSOCIATED VASCULITIS
Clinical trials for ANCA-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANCA-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANCA-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Engineered immune cells take on lupus and other autoimmune diseases
Disease control TerminatedThis early-stage study tests a new treatment called RD06-04, which uses a patient's own immune cells modified to target and destroy faulty B cells. It aims to control active autoimmune diseases like lupus, scleroderma, and Sjögren's syndrome. The main goal is to check safety, but…
Matched conditions: ANCA-ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:44 UTC
-
Immune system reset: CAR T-Cells take on autoimmune diseases
Disease control OngoingThis early-phase study tests a one-time treatment called KYV-101, which uses a patient's own modified immune cells to target and destroy faulty B cells driving autoimmune diseases like lupus, vasculitis, and scleroderma. Up to 24 adults will receive the therapy and be monitored f…
Matched conditions: ANCA-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: David Porter • Aim: Disease control
Last updated May 26, 2026 05:43 UTC
-
CAR-T therapy for autoimmune diseases: trial pulled before start
Disease control TerminatedThis early-phase trial aimed to test a CD19-targeted CAR-T cell therapy (RD06-04) in people with autoimmune diseases like lupus, multiple sclerosis, and myasthenia gravis. The goal was to see if the treatment was safe and could reduce disease activity. However, the study was with…
Matched conditions: ANCA-ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:20 UTC